股本结构
单位：万股
| 公告日期 | 2020-08-05 | 2020-05-06 | 2020-05-06 | 2020-03-02 | 2020-03-02 | 2019-11-06 |
|---|---|---|---|---|---|---|
| 证券总股本 | 10159.86 | 10150.92 | 10134.86 | 10107.40 | 10099.32 | 9390.13 |
| 普通股本 | 10159.86 | 10150.92 | 10134.86 | 10107.40 | 10099.32 | 9390.13 |
| 优先股 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 其他 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 变动日期 | 2020-07-29 | 2020-04-29 | 2020-03-31 | 2020-02-20 | 2019-12-31 | 2019-10-31 |
注释：中概股证券总股本=普通股股本/
存托凭证比例
历史变动
| 公告日期 | 变动后普通股本（万股） | 变动后优先股（万股） | 变动原因 | 变动日期 |
|---|---|---|---|---|
| 2020-08-05 | 10159.86 | 未披露 | 定期报告 | 2020-07-29 |
| 2020-05-06 | 10150.92 | 未披露 | 定期报告 | 2020-04-29 |
| 2020-05-06 | 10134.86 | 未披露 |
更多>>
from December 31, 2019 to March 31, 2020
Issuance of common stock in connection with employee stock plans
Payments of tax withholdings related to exercise of employee stock options
|
2020-03-31 |
| 2020-03-02 | 10107.40 | 未披露 | 定期报告 | 2020-02-20 |
| 2020-03-02 | 10099.32 | 未披露 |
更多>>
from December 31, 2018 to December 31, 2019
Exercise of common stock options
Issuance of common stock in connection with employee stock purchase plan
Issuance of restricted common stock
Issuance of common stock in connection with Ionis sublicense fee
Payments of tax withholdings related to exercise of employee stock awards
|
2019-12-31 |
| 2019-11-06 | 9390.13 | 未披露 | 定期报告 | 2019-10-31 |
| 2019-11-06 | 9388.54 | 未披露 |
更多>>
From June 30, 2019 to September 30, 2019
Exercise of common stock options
Issuance of common stock in connection with employee stock purchase plan
Payments of tax withholdings related to exercise of employee stock awards
|
2019-09-30 |
| 2019-08-07 | 9303.24 | 未披露 | 定期报告 | 2019-08-01 |
| 2019-08-07 | 9292.12 | 未披露 |
更多>>
From March 31, 2019 to June 30, 2019
Exercise of common stock options
|
2019-06-30 |
| 2019-05-09 | 9277.04 | 未披露 | 定期报告 | 2019-05-02 |
| 2019-04-29 | 9276.71 | 未披露 | 定期报告 | 2019-04-29 |
| 2019-05-09 | 9263.54 | 未披露 |
更多>>
From December 31, 2018 to March 31, 2019
Exercise of common stock options
Issuance of common stock in connection with employee stock purchase plan
Issuance of common stock in connection with Ionis sublicense fee
|
2019-03-31 |
| 2019-03-01 | 8943.32 | 未披露 | 定期报告 | 2019-02-20 |
| 2019-03-01 | 8934.60 | 未披露 |
更多>>
From December 31, 2017 to December 31, 2018
Exercise of common stock options
Issuance of common stock in connection with employee stock purchase plan
Issuance of restricted common stock
Issuance of common stock to Ionis in connection with TTR License Agreement
Issuance of common stock to Ionis in connection with TEGSEDI regulatory milestones
|
2018-12-31 |
| 2018-11-28 | 8925.95 | 未披露 | 定期报告 | 2018-11-21 |
| 2018-11-06 | 8921.09 | 未披露 | 定期报告 | 2018-10-31 |
| 2018-11-06 | 8747.13 | 未披露 | 定期报告 | 2018-09-30 |
| 2018-08-07 | 8571.84 | 未披露 | 定期报告 | 2018-07-31 |
| 2018-08-07 | 8568.07 | 未披露 | 定期报告 | 2018-06-30 |
| 2018-05-07 | 8559.32 | 未披露 |
更多>>
As payment for the grant of rights under the License Agreement, we paid an upfront licensing fee of $150.0 million, which was paid through the issuance of 8 million shares of our common stock priced by reference to a recent trading average.To support the commercialization of inotersen and AKCEA-TTR-LRx, Ionis purchased 10.7 million shares of our common stock for $200 million and received an additional 8 million shares in consideration of the upfront licensing fee, increasing Ionis' ownership percentage to approximately 75%.
|
2018-04-30 |
| 2018-04-20 | 6681.88 | 未披露 | 定期报告 | 2018-04-20 |
| 2018-05-07 | 6680.38 | 未披露 | 定期报告 | 2018-03-31 |
| 2018-03-26 | 6672.01 | 未披露 | 定期报告 | 2018-03-21 |
| 2018-02-28 | 6663.07 | 未披露 | 定期报告 | 2018-02-20 |
| 2018-02-28 | 6654.16 | 未披露 |
更多>>
from December 31, 2016 to September 30, 2017
Conversion of convertible preferred stock to common stock
Initial public offering of common stock, net of commissions, underwriting discounts and offering costs
Issuance of common stock in connection with conversion of line of credit with Ionis Pharmaceuticals Inc. together with accrued interest
Issuance of common stock in connection with private placement
|
2017-09-30 |
| 2017-08-09 | 6654.16 | 未披露 | 定期报告 | 2017-08-02 |
| 2017-07-14 | 6419.79 | 未披露 |
更多>>
1.Common stock offered by us 15,625,000 shares.
2.The number of shares of our common stock that will be outstanding after this offering, the concurrent private placement and the conversion of outstanding indebtedness to Ionis is based on 28,884,540 shares of common stock outstanding as of March 31, 2017.
3.reflects a one-for-2.555 reverse stock split of our common stock effected on June 19, 2017.
|
2017-07-14 |
| 2017-08-09 | 未披露 | 2888.45 | 定期报告 | 2017-06-30 |
| 2017-06-20 | 2888.45 | 未披露 |
更多>>
On March 31, 2017, after giving effect to the conversion of all outstanding Series A convertible preferred stock into shares of common stock, there were 28,884,540 shares of common stock issued and outstanding, held of record by one stockholder. Options to purchase 5,063,585 shares of common stock were also outstanding as of March 31, 2017 at a weighted-average exercise price of $6.48 per share.
|
2017-03-31 |
| 2017-03-27 | 未披露 | 7380.00 | 定期报告 | 2016-12-31 |
from December 31, 2019 to March 31, 2020
Issuance of common stock in connection with employee stock plans
Payments of tax withholdings related to exercise of employee stock options
from December 31, 2018 to December 31, 2019
Exercise of common stock options
Issuance of common stock in connection with employee stock purchase plan
Issuance of restricted common stock
Issuance of common stock in connection with Ionis sublicense fee
Payments of tax withholdings related to exercise of employee stock awards
From June 30, 2019 to September 30, 2019
Exercise of common stock options
Issuance of common stock in connection with employee stock purchase plan
Payments of tax withholdings related to exercise of employee stock awards
From March 31, 2019 to June 30, 2019
Exercise of common stock options
From December 31, 2018 to March 31, 2019
Exercise of common stock options
Issuance of common stock in connection with employee stock purchase plan
Issuance of common stock in connection with Ionis sublicense fee
From December 31, 2017 to December 31, 2018
Exercise of common stock options
Issuance of common stock in connection with employee stock purchase plan
Issuance of restricted common stock
Issuance of common stock to Ionis in connection with TTR License Agreement
Issuance of common stock to Ionis in connection with TEGSEDI regulatory milestones
As payment for the grant of rights under the License Agreement, we paid an upfront licensing fee of $150.0 million, which was paid through the issuance of 8 million shares of our common stock priced by reference to a recent trading average.To support the commercialization of inotersen and AKCEA-TTR-LRx, Ionis purchased 10.7 million shares of our common stock for $200 million and received an additional 8 million shares in consideration of the upfront licensing fee, increasing Ionis' ownership percentage to approximately 75%.
from December 31, 2016 to September 30, 2017
Conversion of convertible preferred stock to common stock
Initial public offering of common stock, net of commissions, underwriting discounts and offering costs
Issuance of common stock in connection with conversion of line of credit with Ionis Pharmaceuticals Inc. together with accrued interest
Issuance of common stock in connection with private placement
1.Common stock offered by us 15,625,000 shares.
2.The number of shares of our common stock that will be outstanding after this offering, the concurrent private placement and the conversion of outstanding indebtedness to Ionis is based on 28,884,540 shares of common stock outstanding as of March 31, 2017.
3.reflects a one-for-2.555 reverse stock split of our common stock effected on June 19, 2017.
On March 31, 2017, after giving effect to the conversion of all outstanding Series A convertible preferred stock into shares of common stock, there were 28,884,540 shares of common stock issued and outstanding, held of record by one stockholder. Options to purchase 5,063,585 shares of common stock were also outstanding as of March 31, 2017 at a weighted-average exercise price of $6.48 per share.